Searched for
PIRAMAL PHARMA Q2 REVENUE RISE
Delhivery CEO Sahil Barua says ecommerce driving company’s improved performanceDelhivery's growth is surging, fueled by booming e-commerce, especially from D2C brands and specialized online retailers. Founder Sahil Bar...- Delhivery gets ecommerce bump; Amazon shakes up qcommDelhivery CEO Sahil Barua said ecommerce deliveries are leading the company’s growth. This and more in today’s ETtech Top 5.
- Market wrap: Sensex falls 372 points, Nifty closes below 23,950; Kotak Mahindra Bank drops 3%Indian markets ended lower as Sensex and Nifty snapped a two-session winning streak, pressured by geopolitical tensions in the Middle East ...
- HAL announces final dividend of Rs 10 for FY26. Check record date and other detailsHAL has declared a final dividend of Rs 10 per share (200%) for FY26, subject to shareholder approval at the upcoming AGM. The record date ...
- Residential sales dip to lowest since Jan 2023 amid West Asia war, impacting buyer sentimentResidential sales in India experienced a significant dip in April-June, reaching the lowest point since early 2023. Geopolitical tensions a...
- Over 10% of luxury home sales now come from NRIs across key global markets: Whiteland's Sudeep BhattIndia's luxury housing market is experiencing a structural transformation, attracting significant global capital, particularly from Non-Res...
- Q1 earnings preview: Here’s what Nomura expects from Nestle, Titan, other consumer majors’ June quarter resultsNomura expects consumer staples to deliver a strong start to FY27, forecasting double-digit sales growth for several companies in the June ...
- International visitors to Dubai to return ahead of hotel rate recoveryDubai's tourism is bouncing back, with visitor numbers expected to recover before hotel rates. Accor, a major hospitality player, notes a l...
- Pharma, power & mid-sized banks: Where Mayuresh Joshi is putting money to work right nowIndian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...
- India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...
- India's office market remains cautious despite resilient demand and selective rental gains: ReportIndia's office market saw demand outpace new supply in Q2 FY26, leading to modest rent increases in active areas. Despite a cautious overal...
- Jewellery, defence, and banks: Nuvama's Nikhil Ranka reveals where to find real opportunitiesNuvama Asset Management's Nikhil Ranka identifies key investment opportunities and potential pitfalls in India's equity markets. While reta...
- Buy, Sell or Hold: Goldman Sachs maintains sell on Bharat Dynamics; HDFC Securities maintains buy on IndiaMART InterMESHBrokerages remain divided on two stocks. Goldman Sachs retained its 'Sell' rating on Bharat Dynamics, raising the target price marginally t...
- Bajaj Auto shares fall 2% as firm, subsidiary fall prey to ransomware attackBajaj Auto shares dipped 2% following a ransomware attack on its systems and subsidiary, Bajaj Auto Technology Ltd, on June 23, 2026. The c...
- Ahead of Market: 10 things that will decide stock market action on WednesdaySensex and Nifty plunged over 1% on Tuesday amid global market weakness, IT sector losses, a weaker rupee and fresh foreign fund outflows. ...
- Honasa Consumer to acquire majority stake in Fluence Pharma at Rs 135-crore valuationHonasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...
- Honasa Consumer enters nutraceuticals segment; to acquires 58 pc stake in Fluence PharmaHonasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry in...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Bharat Electronics shares in focus after defence PSU wins orders worth Rs 1,081 croreBharat Electronics shares are in focus following a significant Rs 1,081 crore order win, adding to previous gains. The defence PSU reported...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
Load More
